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of key parameters. CONCLUSION: Clopidogrel as an
alternative to ASA is a cost-effective strategy in secondary
prevention of ischemic events for high-risk atherothrom-
botic patients.
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OBJECTIVES: Fondaparinux, a new synthetic selective
factor XA inhibitor was recently introduced into the
market. This may have widespread implications for
Health care providers that are expected to vary across
countries. We evaluated the cost-effectiveness of fonda-
parinux relative to enoxaparin up to 5-years in the pre-
vention of venous thromboembolism (VTE) following
major orthopaedic surgery and compared the results
across European countries. METHODS: We developed
an economic model and assessed the effect of fonda-
parinux relative to enoxaparin , both given for 7 days, on
patient clinical outcomes and costs in Belgium, Italy, The
Netherlands, Spain, UK. The perspective was that of 
the third party payer. Outcomes are symptomatic deep
vein thrombosis, pulmonary embolism, recurrences, post-
thrombotic syndrome and death. Data on the incidence
of VTE events were derived from four randomised clini-
cal trials comparing enoxaparin with fondaparinux, and
from a review of the literature. Resource consequences
and costs were estimated locally using national or hospi-
tal databases, clinician opinion, literature . . . and vali-
dated by experts. RESULTS: In a hypothetical cohort 
of 1000 patients, weighted to reﬂect the proportion of
patients undergoing hip or knee replacement, or hip frac-
ture surgery in each country, the expected number of VTE
events averted with fondaparinux ranged from 17 to 20
and the number of VTE-related deaths averted is 2 to 3.
Results were consistent across countries: break-even point
in costs was achieved at day 90 or even earlier. The
expected savings with fondaparinux at 5 years would
range between €26,000 and €38,000. These ﬁndings were
found to be robust to wide variations in key assumptions
in the model. CONCLUSIONS: Compared with current
practice in Europe, fondaparinux is a cost-effective and
dominant strategy in the prophylaxis of venous throm-
boembolism following major orthopaedic surgery in all
countries investigated.
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Drug-eluting stents (DES) have been shown to reduce the
risk of restenosis post coronary intervention compared
with conventional stents (CS). However, the cost of DES
is signiﬁcantly higher than CS. OBJECTIVE: To evaluate
the utilization of DES along with clinical indications, out-
comes and cost impact within the cardiac catheterization
lab. METHODS: Demographic, clinical and angiographic
data were collected retrospectively on all patients who
underwent DES implantation between October 15, 2002
and April 15, 2003. Cost data, speciﬁcally stent costs,
were collected concurrently. RESULTS: A cohort of 46
patients was treated with DES, involving 52 vessels and
utilizing 62 stents (56 Cypher, 6 Taxus). Indications for
coronary intervention were stable angina (67.2%) and
ACS/post MI (32.6%). Indications for DES use included
clinical reasons such as diabetes mellitus (15.2%), prior
bypass surgery (19.6%) and renal insufﬁciency (8.7%).
Angiographic indications included: stenosis length 
>18mm (43.4%), vessel diameter <2.5mm (32.6%),
patients with multivessel disease (21.7%) and instent
restenosis (8.7%). Short-term clinical complications
included death but no strokes or myocardial infarctions.
The procedural success was 95.8% (44/46), and the clin-
ical success was 92.5% (43/46). The average number of
DES per patient was 1.35. During the same time period,
351 patients were treated with CS, utilizing 522 stents.
The average number of stents per patient was 1.48. The
total hospital-incurred DES cost was $227,500 for an
average stent cost $4945.65 per patient. In the CS group
the total cost for stents was $496,050 for an average cost
of $1413.25 per patient. The average stent cost per
patient was 3.5 times higher in the DES group than with
CS. CONCLUSIONS: 1) Indications for DES use are con-
sistent with individuals at higher risk for restenosis; 2) the
procedural costs for treating these individuals are signif-
icantly greater; and 3) full 6 month outcomes and cost
data will be available for presentation.
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